Literature DB >> 17764813

Factors affecting human T cell engraftment, trafficking, and associated xenogeneic graft-vs-host disease in NOD/SCID beta2mnull mice.

Bruno Nervi1, Michael P Rettig, Julie K Ritchey, Hanlin L Wang, Gerhard Bauer, Jon Walker, Mark L Bonyhadi, Ronald J Berenson, Julie L Prior, David Piwnica-Worms, Jan A Nolta, John F DiPersio.   

Abstract

OBJECTIVE: Graft-vs-host disease (GVHD) is the major cause of morbidity and mortality after allogeneic hematopoietic stem cell transplantation. Models of immunodeficient mice that consistently and efficiently reconstitute with xenoreactive human T cells would be a valuable tool for the in vivo study of GVHD, as well as other human immune responses.
MATERIALS AND METHODS: We developed a consistent and sensitive model of human GVHD by retro-orbitally injecting purified human T cells into sublethally irradiated nonobese diabetic/severe combined immunodeficient (NOD/SCID)-beta2m(null) recipients. In addition, we characterized for the first time the trafficking patterns and expansion profiles of xenoreactive human T cells in NOD/SCID-beta2m(null) recipients using in vivo bioluminescence imaging.
RESULTS: All NOD/SCID-beta2m(null) mice conditioned with 300 cGy total body irradiation and injected with 1 x 10(7) human T cells exhibited human T-cell engraftment, activation, and expansion, with infiltration of multiple target tissues and a subsequent >20% loss of pretransplantation body weight. Importantly, histological examination of the GVHD target tissues revealed changes consistent with human GVHD. Furthermore, we also showed by in vivo bioluminescence imaging that development of lethal GVHD in the NOD/SCID-beta2m(null) recipients was dependent upon the initial retention and early expansion of human T cells in the retro-orbital sinus cavity.
CONCLUSION: Our NOD/SCID-beta2m(null) mouse model provides a system to study the pathophysiology of acute GVHD induced by human T cells and aids in development of more effective therapies for human GVHD.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17764813      PMCID: PMC2238776          DOI: 10.1016/j.exphem.2007.06.007

Source DB:  PubMed          Journal:  Exp Hematol        ISSN: 0301-472X            Impact factor:   3.084


  63 in total

1.  The human anti-murine xenogeneic cytotoxic response. II. Activated murine antigen-presenting cells directly stimulate human T helper cells.

Authors:  P J Lucas; C V Bare; R E Gress
Journal:  J Immunol       Date:  1995-04-15       Impact factor: 5.422

2.  Delayed infusion of immunocompetent donor cells after bone marrow transplantation breaks graft-host tolerance allows for persistent antileukemic reactivity without severe graft-versus-host disease.

Authors:  B D Johnson; R L Truitt
Journal:  Blood       Date:  1995-06-01       Impact factor: 22.113

3.  Effect of total body irradiation, busulfan-cyclophosphamide, or cyclophosphamide conditioning on inflammatory cytokine release and development of acute and chronic graft-versus-host disease in H-2-incompatible transplanted SCID mice.

Authors:  C Q Xun; J S Thompson; C D Jennings; S A Brown; M B Widmer
Journal:  Blood       Date:  1994-04-15       Impact factor: 22.113

4.  Immunohistology and immunocytology of human T-cell chimerism and graft-versus-host disease in SCID mice.

Authors:  G Hoffmann-Fezer; C Gall; U Zengerle; B Kranz; S Thierfelder
Journal:  Blood       Date:  1993-06-15       Impact factor: 22.113

5.  Multiple defects in innate and adaptive immunologic function in NOD/LtSz-scid mice.

Authors:  L D Shultz; P A Schweitzer; S W Christianson; B Gott; I B Schweitzer; B Tennent; S McKenna; L Mobraaten; T V Rajan; D L Greiner
Journal:  J Immunol       Date:  1995-01-01       Impact factor: 5.422

6.  Improved engraftment of human spleen cells in NOD/LtSz-scid/scid mice as compared with C.B-17-scid/scid mice.

Authors:  D L Greiner; L D Shultz; J Yates; M C Appel; G Perdrizet; R M Hesselton; I Schweitzer; W G Beamer; K L Shultz; S C Pelsue
Journal:  Am J Pathol       Date:  1995-04       Impact factor: 4.307

7.  Human peripheral blood xenografts in the SCID mouse: characterization of immunologic reconstitution.

Authors:  R M Hesselton; R A Koup; M A Cromwell; B S Graham; M Johns; J L Sullivan
Journal:  J Infect Dis       Date:  1993-09       Impact factor: 5.226

8.  Engraftment of human lymphoid cells into newborn SCID mice leads to graft-versus-host disease.

Authors:  F Pflumio; T Lapidot; B Murdoch; B Patterson; J E Dick
Journal:  Int Immunol       Date:  1993-12       Impact factor: 4.823

9.  High level functional engraftment of severe combined immunodeficient mice with human peripheral blood lymphocytes following pretreatment with radiation and anti-asialo GM1.

Authors:  B Shpitz; C A Chambers; A B Singhal; N Hozumi; B J Fernandes; C M Roifman; L M Weiner; J C Roder; S Gallinger
Journal:  J Immunol Methods       Date:  1994-02-28       Impact factor: 2.303

10.  Anti-SCID mouse reactivity shapes the human CD4+ T cell repertoire in hu-PBL-SCID chimeras.

Authors:  M Tary-Lehmann; P V Lehmann; D Schols; M G Roncarolo; A Saxon
Journal:  J Exp Med       Date:  1994-11-01       Impact factor: 14.307

View more
  31 in total

1.  Rapamycin generates anti-apoptotic human Th1/Tc1 cells via autophagy for induction of xenogeneic GVHD.

Authors:  Shoba Amarnath; Francis A Flomerfelt; Carliann M Costanzo; Jason E Foley; Jacopo Mariotti; Daniel M Konecki; Anu Gangopadhyay; Michael Eckhaus; Susan Wong; Bruce L Levine; Carl H June; Daniel H Fowler
Journal:  Autophagy       Date:  2010-05-16       Impact factor: 16.016

2.  Tumor Regression and Delayed Onset Toxicity Following B7-H4 CAR T Cell Therapy.

Authors:  Jenessa B Smith; Evripidis Lanitis; Denarda Dangaj; Elizabeth Buza; Mathilde Poussin; Caitlin Stashwick; Nathalie Scholler; Daniel J Powell
Journal:  Mol Ther       Date:  2016-07-21       Impact factor: 11.454

Review 3.  Advances in bioluminescence imaging of live animal models.

Authors:  Robin S Dothager; Kelly Flentie; Britney Moss; Mei-Hsiu Pan; Aparna Kesarwala; David Piwnica-Worms
Journal:  Curr Opin Biotechnol       Date:  2009-02-23       Impact factor: 9.740

4.  Preclinical Pharmacokinetics and Biodistribution Studies of 89Zr-Labeled Pembrolizumab.

Authors:  Christopher G England; Emily B Ehlerding; Reinier Hernandez; Brian T Rekoske; Stephen A Graves; Haiyan Sun; Glenn Liu; Douglas G McNeel; Todd E Barnhart; Weibo Cai
Journal:  J Nucl Med       Date:  2016-08-04       Impact factor: 10.057

5.  Human peripheral blood CD4 T cell-engrafted non-obese diabetic-scid IL2rγ(null) H2-Ab1 (tm1Gru) Tg (human leucocyte antigen D-related 4) mice: a mouse model of human allogeneic graft-versus-host disease.

Authors:  L Covassin; J Laning; R Abdi; D L Langevin; N E Phillips; L D Shultz; M A Brehm
Journal:  Clin Exp Immunol       Date:  2011-11       Impact factor: 4.330

6.  The PDL1-PD1 axis converts human TH1 cells into regulatory T cells.

Authors:  Shoba Amarnath; Courtney W Mangus; James C M Wang; Fang Wei; Alice He; Veena Kapoor; Jason E Foley; Paul R Massey; Tania C Felizardo; James L Riley; Bruce L Levine; Carl H June; Jeffrey A Medin; Daniel H Fowler
Journal:  Sci Transl Med       Date:  2011-11-30       Impact factor: 17.956

7.  Noninvasive bioluminescent imaging of primary patient acute lymphoblastic leukemia: a strategy for preclinical modeling.

Authors:  David M Barrett; Alix E Seif; Carmine Carpenito; David T Teachey; Jonathan D Fish; Carl H June; Stephan A Grupp; Gregor S D Reid
Journal:  Blood       Date:  2011-08-19       Impact factor: 22.113

8.  Development of novel major histocompatibility complex class I and class II-deficient NOD-SCID IL2R gamma chain knockout mice for modeling human xenogeneic graft-versus-host disease.

Authors:  Steve Pino; Michael A Brehm; Laurence Covassin-Barberis; Marie King; Bruce Gott; Thomas H Chase; Jennifer Wagner; Lisa Burzenski; Oded Foreman; Dale L Greiner; Leonard D Shultz
Journal:  Methods Mol Biol       Date:  2010

9.  Granzyme B is not required for regulatory T cell-mediated suppression of graft-versus-host disease.

Authors:  Sheng F Cai; Xuefang Cao; Anjum Hassan; Todd A Fehniger; Timothy J Ley
Journal:  Blood       Date:  2009-11-13       Impact factor: 22.113

10.  Regulatory T cells and human myeloid dendritic cells promote tolerance via programmed death ligand-1.

Authors:  Shoba Amarnath; Carliann M Costanzo; Jacopo Mariotti; Jessica L Ullman; William G Telford; Veena Kapoor; James L Riley; Bruce L Levine; Carl H June; Timothy Fong; Noel L Warner; Daniel H Fowler
Journal:  PLoS Biol       Date:  2010-02-02       Impact factor: 8.029

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.